Company Overview of Asterand Bioscience, Inc.
Asterand Bioscience, Inc. develops technology and application solutions that provide researchers the tools to investigate and understand cellular reprogramming worldwide. It provides a set of tools for generating iPS cells, as well as cell lines, media, differentiation, rabbit anti-mouse/human, cytokines/proteins, matrices, reprogramming systems, transfection reagents, small molecules, and antibodies; and iPS cell services, training courses, and video protocols. The company serves reprogramming, self-renewal, and differentiation applications. Asterand Bioscience, Inc. was formerly known as Stemgent, Inc. and changed its name to Asterand Bioscience, Inc. in October 2014. The company was incor...
51 Moulton Street
Cambridge, MA 02138
Founded in 2007
Key Executives for Asterand Bioscience, Inc.
Chief Operating Officer and Executive Vice President
Compensation as of Fiscal Year 2015.
Asterand Bioscience, Inc. Key Developments
Stemgent Inc. Launches its New Stemgent StemRNA - SR Reprogramming Kit
Jun 30 15
Stemgent Inc. has launched its new Stemgent StemRNA - SR Reprogramming Kit, the first commercially available RNA reprogramming kit applicable to cellular reprogramming of a blood-derived cell type. This non-viral, non-DNA reprogramming kit combines self-replicative RNA (srRNA) and microRNA technology, providing stem cell researchers with a safe, flexible and cost-effective cellular reprogramming method applicable to both human fibroblasts and blood-derived endothelial progenitor cells (EPCs). EPCs are uniquely genetically stable and can be efficiently established from fresh or cryopreserved human peripheral and cord blood. This latest innovation is being unveiled at the 13th Annual Meeting of the International Society for Stem Cell Research (ISSCR), June 24, 2015 - June 27, 2015 in Stockholm, Sweden.
Stemgent, Inc. and Transposagen Biopharmaceuticals Inc. Enters into Partnership Agreement for Development of Genetically Engineered Induced Pluripotent Stem Cells Services for Pharmaceutical, Biotechnology, Academic and Government Organizations
Feb 18 15
Stemgent, Inc. and Transposagen Biopharmaceuticals Inc. announced that they have entered into a partnership agreement enabling the development of genetically engineered induced pluripotent stem cells (iPSC) services for pharmaceutical, biotechnology, academic and government organizations. The non-exclusive agreement combines Stemgent's industry-recognized expertise in RNA reprogramming with Transposagen's unique genome editing capabilities providing researchers with the convenience of a single point of contact for customer research or disease model systems using patient-specific iPS cells. The newly created service provides customers with a beginning to end solution, starting with Stemgent's expertise in primary cell establishment and iPS cell generation, through genetic manipulation using Transposagen's diverse methods, and ending with a validated cell line that is capable of appropriate differentiation to cardiomyocytes, neurons or hepatocytes.
Asterand Bioscience Seeks Acquisitions
Oct 20 14
Asterand Bioscience, Inc. (Stemgent Inc.) is seeking acquisitions. John Canepa, Chief Financial Officer of Asterand Bioscience, said, "We'll now be looking at acquisitions. We're strategizing that now. There's an opportunity to grow the business here."
Similar Private Companies By Industry
Recent Private Companies Transactions